Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis

Fig. 4

Efficacy of network meta-analysis in early-stage NSCLC patients without PD-L1 selection. OR > 1.00 indicates better efficacy or poorer safety. CT: chemotherapy; Nivo-CT: niv-olumab plus chemotherapy, Tori-CT: Toripalimab plus chemotherapy; Durv-CT: duvalumab plus chemotherapy, Pemb-CT: pembrolizumab plus chemotherapy; Tis-CT: Tislelizumab plus chemotherapy; Ipi + Nivo-CT: ipilimumab plus nivolumab plus chemotherapy

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us